VHCP Management III LLC acquired a new stake in shares of Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 327,777 shares of the company’s stock, valued at approximately $8,358,000. Kiniksa Pharmaceuticals comprises 6.3% of VHCP Management III LLC’s holdings, making the stock its 6th largest holding. VHCP Management III LLC owned 0.66% of Kiniksa Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Vivo Capital LLC increased its stake in Kiniksa Pharmaceuticals by 42.4% in the third quarter. Vivo Capital LLC now owns 264,878 shares of the company’s stock valued at $6,754,000 after purchasing an additional 78,805 shares during the last quarter. American International Group Inc. acquired a new position in Kiniksa Pharmaceuticals in the third quarter valued at $110,000. BlackRock Inc. increased its stake in Kiniksa Pharmaceuticals by 4,405.7% in the third quarter. BlackRock Inc. now owns 450,573 shares of the company’s stock valued at $11,489,000 after purchasing an additional 440,573 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in Kiniksa Pharmaceuticals in the third quarter valued at $435,000. Finally, Alps Advisors Inc. increased its stake in Kiniksa Pharmaceuticals by 30.3% in the third quarter. Alps Advisors Inc. now owns 27,893 shares of the company’s stock valued at $711,000 after purchasing an additional 6,491 shares during the last quarter. Institutional investors own 37.94% of the company’s stock.

Several research firms recently commented on KNSA. Zacks Investment Research lowered Kiniksa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, November 8th. JMP Securities upped their target price on Kiniksa Pharmaceuticals from $33.00 to $44.00 and gave the company an “outperform” rating in a research note on Monday, September 17th. Finally, Wedbush reiterated an “outperform” rating and issued a $31.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, September 11th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $31.75.

NASDAQ:KNSA traded down $0.20 on Wednesday, hitting $20.80. 32,487 shares of the stock were exchanged, compared to its average volume of 53,933. Kiniksa Pharmaceuticals Ltd has a fifty-two week low of $13.04 and a fifty-two week high of $32.88.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings results on Thursday, November 1st. The company reported ($0.51) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.54) by $0.03. Research analysts predict that Kiniksa Pharmaceuticals Ltd will post -2.63 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.watchlistnews.com/vhcp-management-iii-llc-acquires-shares-of-327777-kiniksa-pharmaceuticals-ltd-knsa/2662559.html.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.

See Also: Cost of Capital Explained

Institutional Ownership by Quarter for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.